Ranbaxy Issues Recall of 41 Batches of Atorvastatin

Voluntary recall issued for specific batches of 10-, 20-, 40-mg atorvastatin calcium

MONDAY, Nov. 26 (HealthDay News) -- Ranbaxy Laboratories Ltd., one of India's biggest pharmaceutical companies, has issued a voluntary recall for 41 batches of its generic version of atorvastatin calcium (Lipitor), with the full knowledge of the U.S. Food and Drug Administration.

The voluntary recall, which includes 10-, 20-, and 40-mg doses of atorvastatin, was prompted out of concern that select batches may contain small glass particles, less than 1 mm in size. The recall affects lots packaged in 90 and 500 count bottles and only affects certain select lot numbers. The recall does not affect 80-mg doses of atorvastatin.

A complete list of the recalled lot numbers, bottle sizes, and dosages can be found on Ranbaxy's U.S. website.

"Ranbaxy is proactively recalling the drug product lots out of an abundance of caution, and in keeping the safety of our customers in mind," per a statement on Ranbaxy's U.S. website.

More Information
List of Affected Batches

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events